Nah, they are both CCR5 antagonists. If another
Post# of 148168
(Total Views: 370)
Posted On: 02/22/2021 1:24:53 PM
Re: Number1Stocker #79267
Nah, they are both CCR5 antagonists.
If another drug shows a meaningful impact using a different MOA, they may consider trying them together to see how the results compare. But, that is going to depend on a number of factors.
For example, if the secondary drug is downstream, its effect will be reduced due to Leronlimab working upstream.
If another drug shows a meaningful impact using a different MOA, they may consider trying them together to see how the results compare. But, that is going to depend on a number of factors.
For example, if the secondary drug is downstream, its effect will be reduced due to Leronlimab working upstream.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼